DE60044125D1 - Zusammensetzungen und verfahren zur auslösung einer immunantwort auf basis alphavirus-vektoren-systeme - Google Patents

Zusammensetzungen und verfahren zur auslösung einer immunantwort auf basis alphavirus-vektoren-systeme

Info

Publication number
DE60044125D1
DE60044125D1 DE60044125T DE60044125T DE60044125D1 DE 60044125 D1 DE60044125 D1 DE 60044125D1 DE 60044125 T DE60044125 T DE 60044125T DE 60044125 T DE60044125 T DE 60044125T DE 60044125 D1 DE60044125 D1 DE 60044125D1
Authority
DE
Germany
Prior art keywords
methods
trigging
compositions
vector systems
immune response
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60044125T
Other languages
English (en)
Inventor
John M Polo
Thomas W Dubensky
Ilya Frolov
Jason P Gardner
Gillis Otten
Susan Barnett
David A Driver
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Vaccines and Diagnostics Inc
Original Assignee
Novartis Vaccines and Diagnostics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Vaccines and Diagnostics Inc filed Critical Novartis Vaccines and Diagnostics Inc
Application granted granted Critical
Publication of DE60044125D1 publication Critical patent/DE60044125D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36141—Use of virus, viral particle or viral elements as a vector
    • C12N2770/36143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • AIDS & HIV (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DE60044125T 1999-04-14 2000-04-14 Zusammensetzungen und verfahren zur auslösung einer immunantwort auf basis alphavirus-vektoren-systeme Expired - Lifetime DE60044125D1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US12949899P 1999-04-14 1999-04-14
US14808699P 1999-08-09 1999-08-09
US19136300P 2000-03-22 2000-03-22
PCT/US2000/010722 WO2000061772A2 (en) 1999-04-14 2000-04-14 Compositions and methods for generating an immune response utilizing alphavirus-based vector systems

Publications (1)

Publication Number Publication Date
DE60044125D1 true DE60044125D1 (de) 2010-05-20

Family

ID=27383889

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60044125T Expired - Lifetime DE60044125D1 (de) 1999-04-14 2000-04-14 Zusammensetzungen und verfahren zur auslösung einer immunantwort auf basis alphavirus-vektoren-systeme

Country Status (9)

Country Link
US (1) US7771979B2 (de)
EP (2) EP2196472A3 (de)
JP (1) JP4637368B2 (de)
AT (1) ATE463578T1 (de)
AU (1) AU4366000A (de)
CA (2) CA2373300C (de)
DE (1) DE60044125D1 (de)
DK (1) DK1175497T3 (de)
WO (1) WO2000061772A2 (de)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002080982A2 (en) 2001-01-12 2002-10-17 Chiron Corporation Nucleic acid mucosal immunization
ATE472335T1 (de) 2001-05-31 2010-07-15 Novartis Vaccines & Diagnostic Chimere alphavirus-replikon-partikel
AU2002327614B2 (en) 2001-09-06 2007-12-06 Alphavax, Inc. Alphavirus replicon vector systems
CN1708320A (zh) * 2002-11-07 2005-12-14 郎基·常 经修饰的树突状细胞
ES2890023T3 (es) 2002-12-13 2022-01-17 Alphavax Inc Partículas alfavíricas y métodos de preparación
US20040208848A1 (en) 2002-12-13 2004-10-21 Smith Jonathan F. Multi-antigenic alphavirus replicon particles and methods
DK1608762T3 (da) 2003-03-20 2014-04-07 Alphavax Inc Forbedrede alphavirusreplikoner og hjælperkonstrukter
US7419674B2 (en) 2003-07-11 2008-09-02 Alpha Vax, Inc. Alpha virus-based cytomegalovirus vaccines
US8828957B2 (en) * 2003-12-11 2014-09-09 Microvax, Llc Methods for generating immunity to antigen
AU2005245956B2 (en) 2004-05-18 2011-05-19 Alphavax, Inc. TC-83-derived alphavirus vectors, particles and methods
EP2848692B1 (de) 2004-05-21 2017-08-16 Novartis Vaccines and Diagnostics, Inc. Alphavirus-Vektoren für Influenzavirus-Impfstoffe
CA2611056C (en) 2005-06-01 2016-06-28 California Institute Of Technology Method of targeted gene delivery using viral vectors
EP1945247A1 (de) 2005-10-18 2008-07-23 Novartis Vaccines and Diagnostics, Inc. Mukosale und systemische immunisierungen mit alphavirus-replicon-teilchen
JP5215865B2 (ja) 2005-11-22 2013-06-19 ノバルティス ヴァクシンズ アンド ダイアグノスティクス インコーポレイテッド ノロウイルス抗原およびサポウイルス抗原
EP2520168B1 (de) * 2006-07-21 2014-03-19 California Institute of Technology Zielgesteuerte Genabgabe für die Immunisierung mit Dendritenzellen
US7850977B2 (en) 2007-06-21 2010-12-14 Alphavax, Inc. Promoterless cassettes for expression of alphavirus structural proteins
AU2008314485B9 (en) 2007-10-15 2015-02-26 Jingang Medicine (Australia) Pty Ltd Expression system for modulating an immune response
DK2770061T3 (en) 2009-07-24 2019-01-07 Immune Design Corp NON-INTEGRATING LENTIVIRUS VECTORS
US9795658B2 (en) 2010-04-20 2017-10-24 Admedus Vaccines Pty Ltd Expression system for modulating an immune response
US9422529B2 (en) * 2010-12-22 2016-08-23 The Board Of Regents Of The University Of Texas System Alphavirus compositions and methods of use
WO2012088473A1 (en) * 2010-12-22 2012-06-28 The Board Of Regents Of The University Of Texas System Alphavirus compositions and methods of use
US9487563B2 (en) 2011-01-31 2016-11-08 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Virus-like particles and methods of use
RU2014104090A (ru) 2011-07-06 2015-08-20 Новартис Аг Липосомы с эффективным соотношением n:p для доставки молекул phk
US8323662B1 (en) 2012-03-30 2012-12-04 Immune Design Corp. Methods useful for generating highly mannosylated pseudotyped lentiviral vector particles comprising a Vpx protein
EA038702B1 (ru) 2012-03-30 2021-10-07 Иммьюн Дизайн Корп. Лентивирусные векторные частицы, имеющие улучшенную эффективность трансдукции клеток, экспрессирующих dc-sign
US9713635B2 (en) 2012-03-30 2017-07-25 Immune Design Corp. Materials and methods for producing improved lentiviral vector particles
EP2869842A1 (de) * 2012-07-06 2015-05-13 Novartis AG Immunogene zusammensetzungen und verwendungen davon
EP2895191B1 (de) 2012-09-14 2019-06-05 The U.S.A. as represented by the Secretary, Department of Health and Human Services Brachyury-protein, adenovirale vektoren zur codierung von brachyury-protein und deren verwendung
KR101650364B1 (ko) * 2012-12-05 2016-08-23 더백스 제네틱스 백신 코포레이션, 엘티디. 항원-특이적인 t 세포 반응을 유도하는 면역 강화제로서 사용을 위한 융합 단백질
CA2930693A1 (en) 2013-11-15 2015-05-21 The Board Of Trustees Of The Leland Stanford Junior Unversity Methods of treating heart failure with agonists of hypocretin receptor 2
EP3313863B1 (de) 2015-06-29 2020-12-23 The Board of Trustees of the Leland Stanford Junior University Degronfusionskonstrukte und verfahren zur steuerung der proteinproduktion
CN108289940B (zh) 2015-08-03 2023-01-13 美国卫生和人力服务部 Brachyury缺失突变体、编码brachyury缺失突变体的非酵母载体及其用途
KR20180083437A (ko) 2015-12-09 2018-07-20 애드메더스 백신스 피티와이 리미티드 치료를 위한 면역조절용 조성물
JP2019511255A (ja) 2016-01-11 2019-04-25 バーンダリ，インク． マイクロニードル組成物およびそれを使用する方法
BR112019023477A2 (pt) 2017-05-08 2020-06-30 Gritstone Oncology, Inc. vetores de neoantígeno de alfavírus
BR112020013679A2 (pt) 2018-01-04 2020-12-01 Iconic Therapeutics, Inc. anticorpos de fator antitecidual, conjugados anticorpo-fármaco e métodos relacionados
NL2022538B1 (en) 2019-02-08 2020-08-19 Academisch Ziekenhuis Groningen Methods for providing purified viral particles of Semliki Forest Virus (SFV), preparations obtainable thereby, and uses thereof.
BR122024002387A2 (pt) 2019-05-30 2024-03-12 Gritstone Bio, Inc. Vetores de adenovírus, composição farmacêutica, sequência de nucleotídeo isolada, célula isolada, vetor, kit, usos de um vetor, método para fabricar o vetor, métodos para produzir um vírus e vetor viral
CN116196405A (zh) 2019-12-31 2023-06-02 伊利克斯根治疗公司 核酸和蛋白质向细胞和组织的基于温度的瞬时递送
CN116438308A (zh) 2020-08-06 2023-07-14 磨石生物公司 多表位疫苗盒
WO2023070072A1 (en) 2021-10-21 2023-04-27 The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone Retroelement-generated transcription factor decoys
CA3237482A1 (en) 2021-11-03 2023-05-11 The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone Precise genome editing using retrons
WO2023141602A2 (en) 2022-01-21 2023-07-27 Renagade Therapeutics Management Inc. Engineered retrons and methods of use
WO2023183589A1 (en) 2022-03-25 2023-09-28 The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone Rt-dna fidelity and retron genome editing
WO2023183588A1 (en) 2022-03-25 2023-09-28 The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone Methods of assessing engineered retron activity, and uses thereof
WO2023183627A1 (en) 2022-03-25 2023-09-28 The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone Production of reverse transcribed dna (rt-dna) using a retron reverse transcriptase from exogenous rna
WO2024020346A2 (en) 2022-07-18 2024-01-25 Renagade Therapeutics Management Inc. Gene editing components, systems, and methods of use
WO2024044673A1 (en) 2022-08-24 2024-02-29 The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone Dual cut retron editors for genomic insertions and deletions
WO2024044723A1 (en) 2022-08-25 2024-02-29 Renagade Therapeutics Management Inc. Engineered retrons and methods of use

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5171568A (en) 1984-04-06 1992-12-15 Chiron Corporation Recombinant herpes simplex gb-gd vaccine
CA1341423C (en) 1984-10-31 2003-03-04 Paul A. Luciw Recombinant proteins of viruses associated with lymphadenopathy syndrome and/or acquired immune deficiency syndrome
US5466788A (en) 1985-03-07 1995-11-14 Mycogen Plant Science, Inc. Subgenomic promoter
US5185444A (en) 1985-03-15 1993-02-09 Anti-Gene Deveopment Group Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages
DE3687030T2 (de) 1985-03-15 1993-03-11 James Summerton Stereoregulare polynukleotiden bindende polymere.
US5091309A (en) 1986-01-16 1992-02-25 Washington University Sindbis virus vectors
US4927750A (en) 1986-04-09 1990-05-22 Jeanette Simpson Cell separation process
EP0251575B2 (de) 1986-06-17 2002-11-13 Chiron Corporation Hepatitis-Delta-Diagnostika und Impfstoffe, ihre Herstellung und Verwendung
US5716826A (en) 1988-03-21 1998-02-10 Chiron Viagene, Inc. Recombinant retroviruses
US5217879A (en) 1989-01-12 1993-06-08 Washington University Infectious Sindbis virus vectors
US5026686A (en) 1989-02-01 1991-06-25 Washington University Antiviral peptides
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
WO1990014837A1 (en) 1989-05-25 1990-12-13 Chiron Corporation Adjuvant formulation comprising a submicron oil droplet emulsion
US5185440A (en) 1989-06-20 1993-02-09 North Carolina State University cDNA clone coding for Venezuelan equine encephalitis virus and attenuating mutations thereof
SE9003978D0 (sv) 1990-12-13 1990-12-13 Henrik Garoff Dna expressionssystem baserade paa ett virus replikon
DK0633929T3 (da) 1992-04-01 2004-06-28 Univ Rockefeller Fremgangsmåde til in vitro proliferation af dendritcelleforstadier og deres anvendelse til at producere immunogener
AU6172194A (en) 1993-02-08 1994-08-29 Paravax, Inc. Defective sindbis virus vectors that express (toxoplasma gondii) p30 antigens
WO1995002698A1 (en) 1993-07-12 1995-01-26 Life Technologies, Inc. Composition and methods for transfecting eukaryotic cells
US6015686A (en) 1993-09-15 2000-01-18 Chiron Viagene, Inc. Eukaryotic layered vector initiation systems
US5591579A (en) 1993-12-21 1997-01-07 Washington University Indicator cell line for detecting RNA viruses and method therefor
US5532154A (en) 1994-03-21 1996-07-02 Research Development Foundation Mutated alpha virus
DE4412794A1 (de) 1994-04-14 1995-12-14 Univ Ludwigs Albert Verfahren zur Herstellung von dendritischen Zellen, so erhaltene Zellen und Behälter zur Durchführung dieses Verfahrens
US5505947A (en) 1994-05-27 1996-04-09 The University Of North Carolina At Chapel Hill Attenuating mutations in Venezuelan Equine Encephalitis virus
US5663051A (en) 1994-08-31 1997-09-02 Activated Cell Therapy, Inc. Separation apparatus and method
US5646004A (en) 1994-08-31 1997-07-08 Activated Cell Therapy, Inc. Methods for enriching fetal cells from maternal body fluids
US5648219A (en) 1995-06-07 1997-07-15 Zymogenetics, Inc. Immortalized dendritic cells
JPH11504802A (ja) * 1994-11-30 1999-05-11 カイロン コーポレイション 組換えアルファウイルスベクター
US5648248A (en) 1994-12-30 1997-07-15 Boehringer Ingelheim International Gmbh Methods for producing differentiated cells from immature hematopoietic cells
US5643786A (en) 1995-01-27 1997-07-01 The United States Of America As Represented By The Department Of Health And Human Services Method for isolating dendritic cells
US5871728A (en) 1995-03-31 1999-02-16 University Of Pittsburgh Method of regulating dendritic cell maturation
US5792462A (en) 1995-05-23 1998-08-11 University Of North Carolina At Chapel Hill Alphavirus RNA replicon systems
US5797870A (en) 1995-06-07 1998-08-25 Indiana University Foundation Pericardial delivery of therapeutic and diagnostic agents
US5788963A (en) 1995-07-31 1998-08-04 Pacific Northwest Cancer Foundation Isolation and/or preservation of dendritic cells for prostate cancer immunotherapy
US5811297A (en) 1996-03-07 1998-09-22 Amba Biosciences, Llc Immortalized hematopoietic cell lines, cell system thereof with stromal cells, in vitro, ex vivo and in vivo uses, & in vitro generation of dendritic cells and macrophages
WO1997038087A2 (en) * 1996-04-05 1997-10-16 Chiron Corporation Alphaviral vector with reduced inhibition of cellular macromolecular synthesis
US5843712A (en) 1996-06-06 1998-12-01 The Trustees Of Columbia University In The City Of New York Sindbis virus expression system for recombinant antibody production
US5842723A (en) 1996-11-25 1998-12-01 Burex Automotive America, Inc. Flexible connection arrangement for connecting a pipe of an exhaust system to an engine, especially in a motor vehicle
US5811407A (en) 1997-02-19 1998-09-22 The University Of North Carolina At Chapel Hill System for the in vivo delivery and expression of heterologous genes in the bone marrow
AU754320B2 (en) * 1998-04-08 2002-11-14 University Of North Carolina At Chapel Hill, The Methods and modified cells for the treatment of cancer

Also Published As

Publication number Publication date
US20080226598A1 (en) 2008-09-18
CA2373300A1 (en) 2000-10-19
ATE463578T1 (de) 2010-04-15
EP2196472A3 (de) 2011-04-13
DK1175497T3 (da) 2010-05-31
AU4366000A (en) 2000-11-14
EP1175497B1 (de) 2010-04-07
JP4637368B2 (ja) 2011-02-23
EP2196472A2 (de) 2010-06-16
EP1175497A2 (de) 2002-01-30
CA2760534A1 (en) 2000-10-19
WO2000061772A2 (en) 2000-10-19
WO2000061772A3 (en) 2001-02-08
JP2002541814A (ja) 2002-12-10
CA2373300C (en) 2012-02-21
US7771979B2 (en) 2010-08-10

Similar Documents

Publication Publication Date Title
DE60044125D1 (de) Zusammensetzungen und verfahren zur auslösung einer immunantwort auf basis alphavirus-vektoren-systeme
DE60335010D1 (de) Immunstimulatorische zusammensetzungen und verfahren zur stimulierung einer immunantwort
DE60000011T2 (de) Informationsaufzeichnungsmedium, Vorrichtung und Verfahren zur nachträglichen Aufzeichnung auf dem Informationsaufzeichnungsmedium
DE69330616D1 (de) Einführbare, expandierbare Vorrichtung zur Erzeugung eines anatomischen Arbeitsraums
DE69918089D1 (de) Btk inhibitoren und verfahren zur identifizierung und verwendung
ATE425761T1 (de) Agarwood aus kulturmassigem anbau
DE69301309D1 (de) Gerät zur simulation der physiologischen und physiopathologischen zustände.
DE69804810T2 (de) Kommunikationssysteme bzw. verfahren, bei denen eine selektive und rekursive dekodierung verwendet wird
ITBO970115A0 (it) Procedimento per sterilizzare terreni e relativa attrzzatura.
DE69300024T2 (de) Vorrichtung zur Erzeugung von Bezugsspannungen.
DE69022926T2 (de) Virtuelle Mikrophonanlage und dafür bestimmtes Verfahren.
DE69824315D1 (de) Verfahren zur charakterisierung komplexer flüssigkeiten und vorrichtungen zur durchführung des verfahrens
DE10085297T1 (de) Verfahren und Vorrichtung zur Erzeugung einer Bewegungsillusion
DE69113591T2 (de) Verfahren und gerät zur generierung von pulsen.
ATA143389A (de) Rollvorrichtung zur anbringung an stuhlbeinen od. dgl.
AR248425A1 (es) Plasmidos pd143 y pd148 y vectores que contienen dichos plasmidos, cepa de saccharomyces cerevisiae, de lactococcal lactis y de e. coli ncimb 40217.
DE69108166T2 (de) Verfahren und Vorrichtung zur Regelung eines Wechselstromgenerators.
DE60040340D1 (de) Einrichtung zur darstellung von flugführungsinformation
DE60024777D1 (de) Verfahren zur halbleiterbaustein-simulation und simulator
DE29816100U1 (de) Vorrichtung zur Krafterzeugung
NL1007271A1 (nl) Werkwijze en inrichting voor het verdoven van gevogelte.
DE60116741D1 (de) Schaltung, verfahren und system zur erzeugung einer nichtlinearen transfercharakteristik
DE69933083D1 (de) Gerät zur Herstellung eines Informationsträgers und der Informationsträger
IT1304662B1 (it) Procedimento e dispositivo di stampa su oggetti tridimensionali.
DE29905966U1 (de) Vorrichtung zur Erzeugung von Bodennebel

Legal Events

Date Code Title Description
8364 No opposition during term of opposition